Skin Manifestations of Inflammatory Bowel Disease

被引:91
|
作者
Greuter, Thomas [1 ]
Navarini, Alexander [2 ]
Vavricka, Stephan R. [1 ,3 ]
机构
[1] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland
[2] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland
[3] Triemli Hosp Zurich, Div Gastroenterol & Hepatol, Dept Med, Birmensdorferstr 497, CH-8063 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
Inflammatory bowel disease; Extraintestinal manifestations; Erythema nodosum; Pyoderma gangrenosum; Anti-TNF-induced skin lesions; METASTATIC CROHNS-DISEASE; CHRONIC ERYTHEMA-NODOSUM; EVIDENCE-BASED CONSENSUS; NECROSIS FACTOR THERAPY; EXTRAINTESTINAL MANIFESTATIONS; PYODERMA-GANGRENOSUM; SWEETS-SYNDROME; ULCERATIVE-COLITIS; CUTANEOUS MANIFESTATIONS; MAINTENANCE THERAPY;
D O I
10.1007/s12016-017-8617-4
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Inflammatory bowel disease (IBD) with its two main subtypes Crohn's disease and ulcerative colitis is not restricted to the gastrointestinal tract. Indeed, so-called extraintestinal manifestations (EIMs) are frequent and considerably affect morbidity and mortality. The prevalence of EIMs ranges from 6 to 47%. In up to one quarter of the patients, EIMs can present even before an IBD diagnosis is established. The pathophysiology of EIMs remains elusive, although data from clinical trials demonstrating anti-tumor necrosis factor (TNF) efficacy suggest a common pathogenic link between intestinal and extraintestinal disease activity. However, not all EIMs parallel intestinal disease. Skin lesions are usually classified based on their pathophysiological association with the underlying intestinal disease into four categories: (1) specific, (2) reactive, (3) associated, and (4) treatment-induced manifestations. Cutaneous manifestations include erythema nodosum (EN), pyoderma gangrenosum (PG), Sweet's syndrome, and oral lesions, with EN being the most commonly reported and PG showing the most debilitating disease course. Anti-TNF-induced skin reactions are a new, but increasingly recognized phenomenon, which can be eventually misinterpreted as psoriatic lesions. Medical treatment modalities are limited with topical and systemic steroids being the most frequently employed agents. If EIMs parallel intestinal disease activity, the therapeutic cornerstone usually is the management of underlying intestinal disease activity rather than direct treatment of the EIMs. However, increasing evidence for anti-TNF agents' efficacy in EIM management has changed the approach to complicating and debilitating disease courses. In the case of anti-TNF-induced lesions, topical steroids are usually sufficient and discontinuation of anti-TNF is seldom warranted. In this review, we summarize current knowledge on cutaneous EIMs, their diagnostic criteria and clinical presentation, natural history, pathogenesis, and treatment options.
引用
收藏
页码:413 / 427
页数:15
相关论文
共 50 条
  • [1] Skin Manifestations of Inflammatory Bowel Disease
    Thomas Greuter
    Alexander Navarini
    Stephan R. Vavricka
    [J]. Clinical Reviews in Allergy & Immunology, 2017, 53 : 413 - 427
  • [2] Skin manifestations of inflammatory bowel disease
    Timani, Shereen
    Mutasim, Diya F.
    [J]. CLINICS IN DERMATOLOGY, 2008, 26 (03) : 265 - 273
  • [3] Skin manifestations of inflammatory bowel disease
    Huang, Brian L.
    Chandra, Stephanie
    Shih, David Quan
    [J]. FRONTIERS IN PHYSIOLOGY, 2012, 3
  • [4] Skin manifestations of pediatric inflammatory bowel disease
    Martin de Carpi, J.
    Chavez Caraza, K.
    Vicente Villa, M. A.
    Gonzalez Ensenat, M. A.
    Vilar Escrigas, P.
    Vila Miravet, V.
    Guallarte Alias, P.
    Varea Calderon, V.
    [J]. ANALES DE PEDIATRIA, 2009, 70 (06): : 570 - 577
  • [5] Skin manifestations of inflammatory bowel disease: clinical and therapeutic issues
    Delaporte, E
    [J]. IBD AND SALICYLATES - 3, 1998, 20 (01): : 209 - 213
  • [6] A Review of Cutaneous Extraintestinal Manifestations of Inflammatory Bowel Disease in Skin of Color
    Odufalu, Florence-Damilola
    Gonzalez, Sarah
    Hurtado, Arielle Carolina Mora
    Hsiao, Jennifer
    Xu, Mimi
    Elbuluk, Nada
    [J]. INFLAMMATORY BOWEL DISEASES, 2024,
  • [7] Infliximab-induced skin manifestations in patients with inflammatory bowel disease
    Hellstrom, Alec Eligius
    Farkkila, Martti
    Kolho, Kaija-Leena
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (05) : 563 - 571
  • [8] Disease-related and drug-induced skin manifestations in inflammatory bowel disease
    Hindryckx, Pieter
    Novak, Gregor
    Costanzo, Antonio
    Danese, Silvio
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (03) : 203 - 214
  • [9] Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study
    Roth, Nina
    Biedermann, Luc
    Fournier, Nicolas
    Butter, Matthias
    Vavricka, Stephan R.
    Navarini, Alexander A.
    Rogler, Gerhard
    Scharl, Michael
    [J]. PLOS ONE, 2019, 14 (01):
  • [10] Corneal Manifestations of Inflammatory Bowel Disease
    Czompa, Levente
    Barta, Zsolt
    Ziad, Hassan
    Nemeth, Gabor
    Rentka, Aniko
    Aszalos, Zsuzsa
    Zold, Eva
    Gesztelyi, Rudolf
    Zsuga, Judit
    Szodoray, Peter
    Kemeny-Beke, Adam
    [J]. SEMINARS IN OPHTHALMOLOGY, 2019, 34 (7-8) : 543 - 550